{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=55",
    "query": {
      "intervention": "IV Abraxane",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 1429,
    "total_pages": 143,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=56&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=54&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T04:33:29.455Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02514551",
      "title": "A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 245,
      "start_date": "2015-10-12",
      "completion_date": "2018-12-28",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Westwood, Kansas • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02514551"
    },
    {
      "nct_id": "NCT06840886",
      "title": "A Study of PHST001 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Cholangiocarcinoma",
        "CNS Tumor",
        "Breast Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Carcinosarcoma, Ovarian"
      ],
      "interventions": [
        {
          "name": "PHST001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Mirvetuximab Soravtansine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Pheast Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 426,
      "start_date": "2025-03-31",
      "completion_date": "2031-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 20,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06840886"
    },
    {
      "nct_id": "NCT01220154",
      "title": "Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer",
        "No Prior Chemotherapy"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David O'Malley",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2011-04-28",
      "completion_date": "2023-07-17",
      "has_results": false,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 1,
      "location_summary": "Hilliard, Ohio",
      "locations": [
        {
          "city": "Hilliard",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01220154"
    },
    {
      "nct_id": "NCT02327169",
      "title": "A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Nonhematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "MLN2480",
          "type": "DRUG"
        },
        {
          "name": "MLN0128",
          "type": "DRUG"
        },
        {
          "name": "Alisertib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2015-01-14",
      "completion_date": "2018-07-02",
      "has_results": true,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02327169"
    },
    {
      "nct_id": "NCT01822756",
      "title": "An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2013-04",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2018-02-12",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Gainesville, Florida • Sarasota, Florida + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01822756"
    },
    {
      "nct_id": "NCT01005329",
      "title": "Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Adenosquamous Carcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Stage IA Uterine Corpus Cancer AJCC v7",
        "Stage IB Uterine Corpus Cancer AJCC v7",
        "Stage II Uterine Corpus Cancer AJCC v7",
        "Stage IIIA Uterine Corpus Cancer AJCC v7",
        "Stage IIIB Uterine Corpus Cancer AJCC v7",
        "Stage IIIC Uterine Corpus Cancer AJCC v7",
        "Stage IVA Uterine Corpus Cancer AJCC v7",
        "Stage IVB Uterine Corpus Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2009-11-06",
      "completion_date": "2013-09-22",
      "has_results": true,
      "last_update_posted_date": "2018-03-15",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 38,
      "location_summary": "Berkeley, California • Walnut Creek, California • Colorado Springs, Colorado + 31 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01005329"
    },
    {
      "nct_id": "NCT07793942",
      "title": "A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplam",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "MK-2010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin or Levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Belzutifan",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Epinephrine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2026-10-21",
      "completion_date": "2030-07-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 4,
      "location_summary": "Belleville, New Jersey • East Brunswick, New Jersey • Maumee, Ohio + 1 more",
      "locations": [
        {
          "city": "Belleville",
          "state": "New Jersey"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07793942"
    },
    {
      "nct_id": "NCT00821964",
      "title": "Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Recurrent Breast Cancer",
        "Skin Metastases",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "imiquimod",
          "type": "DRUG"
        },
        {
          "name": "Abraxane",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "RNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-12",
      "completion_date": "2012-11-29",
      "has_results": true,
      "last_update_posted_date": "2018-01-02",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821964"
    },
    {
      "nct_id": "NCT01455532",
      "title": "A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Malignant"
      ],
      "interventions": [
        {
          "name": "Iniparib (SAR240550-BSI-201)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Placlitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2011-11",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-10-22",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Augusta, Georgia + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01455532"
    },
    {
      "nct_id": "NCT07546812",
      "title": "Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-negative",
        "Gastroesophageal Junction",
        "Esophageal Adenocarcinoma",
        "Gastric Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Denikitug",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2026-08-07",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-19T04:33:29.455Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Albany, New York • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07546812"
    }
  ]
}